Does Rallies show Form 4 insider transactions for TELA?

Yes. Rallies tracks TELA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is TELA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TELA. It does not provide personalized investment advice.

TELA (TELA Bio, Inc. Common Stock) Stock Analysis - Insider Trades

TELA Bio, Inc. Common Stock (TELA) is a publicly traded Healthcare sector company. As of May 21, 2026, TELA trades at $0.91 with a market cap of $37.16M and a P/E ratio of -1.23. TELA moved +12.15% today. Year to date, TELA is -13.73%; over the trailing twelve months it is -28.65%. Its 52-week range spans $0.50 to $3.26. Analyst consensus is strong buy with an average price target of $2.00. Rallies surfaces TELA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading TELA stock inside the company?

Recent TELA insider activity includes EW HEALTHCARE PARTNERS FUND 2, L.P. bought 3.60M, Cuca Roberto bought 64.44K, Talmo Paul bought 22.22K, KOBLISH ANTONY bought 88.89K, and Firestone Gregory A. bought 6.67K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

TELA Key Metrics

Key financial metrics for TELA
Metric	Value
Price	$0.91
Market Cap	$37.16M
P/E Ratio	-1.23
EPS	$-0.79
Dividend Yield	0.00%
52-Week High	$3.26
52-Week Low	$0.50
Volume	48
Avg Volume	0
Revenue (TTM)	$80.81M
Net Income	$-39.84M
Gross Margin	67.25%

Recent TELA Insider Trades

EW HEALTHCARE PARTNERS FUND 2, L.P. bought 3.60M (~$4.00M) on Nov 17, 2025.
Cuca Roberto bought 64.44K (~$145.00K) on Oct 24, 2024.
Talmo Paul bought 22.22K (~$50.00K) on Oct 24, 2024.
KOBLISH ANTONY bought 88.89K (~$200.00K) on Oct 24, 2024.
Firestone Gregory A. bought 6.67K (~$15.00K) on Oct 24, 2024.

Latest TELA News

TELA Bio Reports Q1 European Growth, Unveils U.S. Clinical Partnerships — May 13, 2026
TELA Bio Q1 Revenue Rises 3% to $19.1M, Europe Sales Up 41% — May 12, 2026
TELA Bio Exceeds Q1 Guidance with $19M Revenue, Names Four New Board Members — Apr 30, 2026
TELA Bio Lowers 2026 Growth Guidance to 8% After Sales Reorg — Mar 25, 2026
TELA Bio Posts 18% Q4 Revenue Rise to $20.9M, Secures $70M Credit Facility — Mar 24, 2026

TELA Analyst Consensus

4 analysts cover TELA: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $2.00.

Common questions about TELA

Who is trading TELA stock inside the company?: Recent TELA insider activity includes EW HEALTHCARE PARTNERS FUND 2, L.P. bought 3.60M, Cuca Roberto bought 64.44K, Talmo Paul bought 22.22K, KOBLISH ANTONY bought 88.89K, and Firestone Gregory A. bought 6.67K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for TELA?: Yes. Rallies tracks TELA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is TELA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TELA. It does not provide personalized investment advice.